Halozyme Therapeutics Net Worth
Halozyme Therapeutics Net Worth Breakdown | HALO |
Halozyme Therapeutics Net Worth Analysis
Halozyme Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Halozyme Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Halozyme Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Halozyme Therapeutics' net worth analysis. One common approach is to calculate Halozyme Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Halozyme Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Halozyme Therapeutics' net worth. This approach calculates the present value of Halozyme Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Halozyme Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Halozyme Therapeutics' net worth. This involves comparing Halozyme Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Halozyme Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Halozyme Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Halozyme Therapeutics' net worth research are outlined below:
| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: How Is Halozyme Therapeutics Navigating Market Trends |
Halozyme Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Halozyme Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Halozyme Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Halozyme Therapeutics Target Price Consensus
Halozyme target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Halozyme Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Buy |
Most Halozyme analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Halozyme stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Halozyme Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationHalozyme Therapeutics Target Price Projection
Halozyme Therapeutics' current and average target prices are 65.16 and 65.38, respectively. The current price of Halozyme Therapeutics is the price at which Halozyme Therapeutics is currently trading. On the other hand, Halozyme Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Halozyme Therapeutics Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Halozyme Therapeutics Target Price
Know Halozyme Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Halozyme Therapeutics' institutional investor refers to the entity that pools money to purchase Halozyme Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.9 M | Goldman Sachs Group Inc | 2024-12-31 | 1.9 M | Northern Trust Corp | 2024-12-31 | 1.8 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.8 M | Gw&k Investment Management, Llc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.5 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.5 M | Artisan Partners Limited Partnership | 2024-12-31 | 1.4 M | Blackrock Inc | 2024-12-31 | 17.6 M | Vanguard Group Inc | 2024-12-31 | 13.3 M |
Follow Halozyme Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.95 B.Market Cap |
|
Project Halozyme Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.36 | 0.37 | |
| Return On Capital Employed | 0.29 | 0.30 | |
| Return On Assets | 0.22 | 0.23 | |
| Return On Equity | 1.22 | 1.28 |
When accessing Halozyme Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Halozyme Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Halozyme Therapeutics' profitability and make more informed investment decisions.
Evaluate Halozyme Therapeutics' management efficiency
Halozyme Therapeutics has return on total asset (ROA) of 0.1816 % which means that it generated a profit of $0.1816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.9842 %, meaning that it created $1.9842 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to grow to 0.37. Also, Return On Capital Employed is likely to grow to 0.30. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 22nd of March 2025, Debt To Assets is likely to grow to 0.90, while Other Current Assets are likely to drop about 22.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.87 | 3.01 | |
| Tangible Book Value Per Share | (3.59) | (3.41) | |
| Enterprise Value Over EBITDA | 11.35 | 11.92 | |
| Price Book Value Ratio | 16.67 | 15.83 | |
| Enterprise Value Multiple | 11.35 | 11.92 | |
| Price Fair Value | 16.67 | 15.83 | |
| Enterprise Value | 2 B | 2 B |
The decision-making processes within Halozyme Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 8.7217 | Revenue | Quarterly Revenue Growth 0.295 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Halozyme Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Halozyme Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Halozyme Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Halozyme Therapeutics Corporate Filings
| 18th of March 2025 Other Reports | ViewVerify | |
F4 | 3rd of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Halozyme Therapeutics Earnings Estimation Breakdown
The calculation of Halozyme Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Halozyme Therapeutics is estimated to be 0.972 with the future projection ranging from a low of 0.85 to a high of 1.08. Please be aware that this consensus of annual earnings estimates for Halozyme Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.85 Lowest | Expected EPS | 1.08 Highest |
Halozyme Therapeutics Earnings Projection Consensus
Suppose the current estimates of Halozyme Therapeutics' value are higher than the current market price of the Halozyme Therapeutics stock. In this case, investors may conclude that Halozyme Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Halozyme Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 10 | 88.99% | 1.26 | 0.972 | 3.43 |
Halozyme Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Halozyme Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Halozyme Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Halozyme Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Halozyme Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Halozyme Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Halozyme Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Halozyme Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Halozyme Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-18 | 2024-12-31 | 1.1588 | 1.26 | 0.1012 | 8 | ||
2024-10-31 | 2024-09-30 | 0.98 | 1.27 | 0.29 | 29 | ||
2024-08-06 | 2024-06-30 | 0.76 | 0.91 | 0.15 | 19 | ||
2024-05-07 | 2024-03-31 | 0.7 | 0.79 | 0.09 | 12 | ||
2024-02-20 | 2023-12-31 | 0.83 | 0.82 | -0.01 | 1 | ||
2023-11-06 | 2023-09-30 | 0.71 | 0.75 | 0.04 | 5 | ||
2023-08-08 | 2023-06-30 | 0.63 | 0.74 | 0.11 | 17 | ||
2023-05-09 | 2023-03-31 | 0.48 | 0.47 | -0.01 | 2 | ||
2023-02-21 | 2022-12-31 | 0.47 | 0.48 | 0.01 | 2 | ||
2022-11-08 | 2022-09-30 | 0.51 | 0.74 | 0.23 | 45 | ||
2022-08-09 | 2022-06-30 | 0.5 | 0.53 | 0.03 | 6 | ||
2022-05-10 | 2022-03-31 | 0.49 | 0.47 | -0.02 | 4 | ||
2022-02-22 | 2021-12-31 | 0.41 | 0.42 | 0.01 | 2 | ||
2021-11-02 | 2021-09-30 | 0.42 | 0.51 | 0.09 | 21 | ||
2021-08-09 | 2021-06-30 | 0.41 | 0.62 | 0.21 | 51 | ||
2021-05-10 | 2021-03-31 | 0.32 | 0.37 | 0.05 | 15 | ||
2021-02-23 | 2020-12-31 | 0.53 | 0.5 | -0.03 | 5 | ||
2020-11-02 | 2020-09-30 | 0.19 | 0.25 | 0.06 | 31 | ||
2020-08-10 | 2020-06-30 | 0.25 | 0.19 | -0.06 | 24 | ||
2020-05-11 | 2020-03-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2020-02-24 | 2019-12-31 | -0.15 | -0.24 | -0.09 | 60 | ||
2019-11-12 | 2019-09-30 | -0.12 | -0.17 | -0.05 | 41 | ||
2019-08-06 | 2019-06-30 | -0.14 | -0.1 | 0.04 | 28 | ||
2019-05-07 | 2019-03-31 | 0.01 | 0.01 | 0.0 | 0 | ||
2019-02-21 | 2018-12-31 | -0.03 | -0.01 | 0.02 | 66 | ||
2018-11-06 | 2018-09-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2018-08-07 | 2018-06-30 | -0.22 | -0.16 | 0.06 | 27 | ||
2018-05-10 | 2018-03-31 | -0.22 | -0.19 | 0.03 | 13 | ||
2018-02-20 | 2017-12-31 | 0.72 | 0.85 | 0.13 | 18 | ||
2017-11-07 | 2017-09-30 | -0.1 | 0.02 | 0.12 | 120 | ||
2017-08-08 | 2017-06-30 | -0.24 | -0.23 | 0.01 | 4 | ||
2017-05-09 | 2017-03-31 | -0.25 | -0.26 | -0.01 | 4 | ||
2017-02-28 | 2016-12-31 | -0.28 | -0.21 | 0.07 | 25 | ||
2016-11-07 | 2016-09-30 | -0.27 | -0.23 | 0.04 | 14 | ||
2016-08-09 | 2016-06-30 | -0.27 | -0.21 | 0.06 | 22 | ||
2016-05-09 | 2016-03-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2016-02-29 | 2015-12-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2015-11-09 | 2015-09-30 | -0.16 | -0.19 | -0.03 | 18 | ||
2015-08-10 | 2015-06-30 | -0.09 | 0.02 | 0.11 | 122 | ||
2015-05-11 | 2015-03-31 | -0.13 | -0.12 | 0.01 | 7 | ||
2015-03-02 | 2014-12-31 | -0.06 | -0.04 | 0.02 | 33 | ||
2014-11-10 | 2014-09-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2014-08-11 | 2014-06-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2014-05-12 | 2014-03-31 | -0.14 | -0.22 | -0.08 | 57 | ||
2014-02-27 | 2013-12-31 | -0.16 | -0.19 | -0.03 | 18 | ||
2013-11-08 | 2013-09-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2013-08-07 | 2013-06-30 | -0.13 | -0.2 | -0.07 | 53 | ||
2013-05-08 | 2013-03-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2013-02-25 | 2012-12-31 | -0.15 | -0.04 | 0.11 | 73 | ||
2012-11-08 | 2012-09-30 | -0.14 | -0.18 | -0.04 | 28 | ||
2012-08-06 | 2012-06-30 | -0.15 | -0.13 | 0.02 | 13 | ||
2012-05-07 | 2012-03-31 | -0.11 | -0.14 | -0.03 | 27 | ||
2012-03-09 | 2011-12-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2011-11-07 | 2011-09-30 | -0.04 | 0.05 | 0.09 | 225 | ||
2011-08-05 | 2011-06-30 | -0.13 | 0.03 | 0.16 | 123 | ||
2011-05-06 | 2011-03-31 | -0.12 | -0.1 | 0.02 | 16 | ||
2010-11-05 | 2010-09-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2010-08-06 | 2010-06-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2010-05-07 | 2010-03-31 | -0.16 | -0.13 | 0.03 | 18 | ||
2010-03-12 | 2009-12-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2009-11-06 | 2009-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2009-08-07 | 2009-06-30 | -0.17 | -0.21 | -0.04 | 23 | ||
2009-05-08 | 2009-03-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2009-03-13 | 2008-12-31 | -0.13 | -0.21 | -0.08 | 61 | ||
2008-11-06 | 2008-09-30 | -0.13 | -0.14 | -0.01 | 7 | ||
2008-08-08 | 2008-06-30 | -0.13 | -0.14 | -0.01 | 7 | ||
2008-05-08 | 2008-03-31 | -0.12 | -0.13 | -0.01 | 8 | ||
2008-03-13 | 2007-12-31 | -0.08 | -0.11 | -0.03 | 37 | ||
2007-11-08 | 2007-09-30 | -0.06 | -0.09 | -0.03 | 50 | ||
2007-08-09 | 2007-06-30 | -0.04 | -0.07 | -0.03 | 75 | ||
2007-05-10 | 2007-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2007-03-08 | 2006-12-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2006-11-09 | 2006-09-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2006-08-10 | 2006-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2006-05-10 | 2006-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2006-03-23 | 2005-12-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2005-11-11 | 2005-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2005-08-08 | 2005-06-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2005-05-13 | 2005-03-31 | -0.06 | -0.06 | 0.0 | 0 | ||
2005-03-09 | 2004-12-31 | -0.07 | -0.05 | 0.02 | 28 | ||
2004-11-12 | 2004-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2004-08-16 | 2004-06-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2004-06-01 | 2004-03-31 | -0.03 | -0.0832 | -0.0532 | 177 |
Halozyme Therapeutics Corporate Management
| Mark Esq | Senior Officer | Profile | |
| Kristin Schwartzbauer | Head Quality | Profile | |
| Gary Grote | Chief Officer | Profile | |
| Nicole LaBrosse | CFO Director | Profile | |
| MD MBA | Chief Officer | Profile | |
| Amy Fox | Senior Resources | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.